Paul K. Wotton, a director at Vericel Corp (NASDAQ:VCEL), recently sold 2,600 shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The shares were sold at a price of $58.72 each, totaling approximately $152,672. Following this transaction, Wotton holds 27,402 shares of Vericel. The sale was executed on December 4, 2024, with the filing made public on December 5, 2024.The transaction occurs as Vericel, currently valued at $2.8 billion, demonstrates strong market performance with a 63% gain year-to-date. The company maintains a "GREAT" financial health rating according to InvestingPro analysis, with analysts setting price targets between $56 and $66. For deeper insights into Vericel's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Vericel Corporation announced a record Q3 revenue of $58 million, a significant 27% increase from the previous year. This growth was largely driven by a 19% rise in MACI revenue to $44.7 million and a 66% surge in total Burn Care revenue to $13.2 million. The company also indicated progress in regulatory approvals, contributing to their optimistic outlook for 2025. Analyst Joe Mara, however, cautioned about a slower rate of margin expansion in 2025 due to depreciation from new facilities. On a positive note, Vericel achieved significant regulatory milestones, including FDA approvals that could boost future revenue. The company's leadership, including Nick Colangelo, expressed confidence for a strong finish to 2024 and continued growth into the following year. These are recent developments and part of the company's ongoing efforts to enhance long-term growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.